doi:10.3969/j.issn.1004-583X.2026.05.014

Abstract

CLC Number:

R692.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.05.014

https://www.lchc.cn/EN/Y2026/V41/I5/475

References 45

[1]	Kung CW, Chou YH. Acute kidney disease: An overview of the epidemiology, pathophysiology, and management[J]. Kidney Res Clin Pract, 2023, 42(6): 686-699.doi: 10.23876/j.krcp.23.001.
[2]	Pan HC, Yang SY, Chiou TT, et al. Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: A systematic review and meta-analysis[J]. Crit Care, 2022, 26(1): 349.doi: 10.1186/s13054-022-04223-6.
[3]	Malaeb H, Zilka S, Jarden A, et al. Multicenter evaluation of the pronephro aki^TM assay performance and stability in pediatric patients[J]. Clin Chim Acta, 2025, 578: 120511.doi: 10.1016/j.cca.2025.120511.
[4]	Bufkin KB, Silva J. The xpresscard point-of-care test for human neutrophil gelatinase-associated lipocalin enhances the prediction of acute kidney injury[J]. J Clin Med, 2024, 13(24):7564.doi: 10.3390/jcm13247564.
[5]	Albert C, Haase M, Albert A, et al. Biomarker-guided risk assessment for acute kidney injury: Time for clinical implementation?[J]. Ann Lab Med, 2021, 41(1): 1-15.doi: 10.3343/alm.2021.41.1.1. pmid: 32829575
[6]	Yang X, Chen C, Tian J, et al. Urinary angiotensinogen level predicts aki in acute decompensated heart failure: A prospective, two-stage study[J]. J Am Soc Nephrol, 2015, 26(8): 2032-2041.doi: 10.1681/asn.2014040408. pmid: 25722365
[7]	Akin A, Demir AK, Özmen ZC. Serum and urinary angiotensinogen levels as prognostic indicators in acute kidney injury: A prospective study[J]. Rev Assoc Med Bras, 2023, 69(12): e20230716.doi: 10.1590/1806-9282.20230716.
[8]	Kim KS, Yang HY, Song H, et al. Identification of a sensitive urinary biomarker, selenium-binding protein 1, for early detection of acute kidney injury[J]. J Toxicol Environ Health A, 2017, 80(9): 453-464.doi: 10.1080/15287394.2017.1299655.
[9]	Zhao W, Nikolic-Paterson DJ, Li K, et al. Selenium binding protein 1 protects renal tubular epithelial cells from ferroptosis by upregulating glutathione peroxidase 4[J]. Chem Biol Interact, 2024, 393: 110944.doi: 10.1016/j.cbi.2024.110944.
[10]	Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury[J]. Crit Rev Clin Lab Sci, 2021, 58(5): 354-368.doi: 10.1080/10408363.2021.1879000.
[11]	Zhang H, Lang H, Ma M, et al. Decreased preoperative urinary uromodulin as a predictor of acute kidney injury and perioperative kidney dysfunction in patients undergoing cardiac surgery: A prospective cohort study[J]. Clin Chim Acta, 2022, 530: 1-7.doi: 10.1016/j.cca.2022.02.008. pmid: 35176269
[12]	You R, Zheng H, Xu L, et al. Decreased urinary uromodulin is potentially associated with acute kidney injury: A systematic review and meta-analysis[J]. J Intensive Care, 2021, 9(1): 70.doi: 10.1186/s40560-021-00584-2. pmid: 34782019
[13]	Bagshaw SM, Al-Khafaji A, Artigas A, et al. External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury[J]. Crit Care, 2021, 25(1): 185.doi: 10.1186/s13054-021-03618-1.
[14]	Hoste E, Bihorac A, Al-Khafaji A, et al. Identification and validation of biomarkers of persistent acute kidney injury: The ruby study[J]. Intensive Care Med, 2020, 46(5): 943-953.doi: 10.1007/s00134-019-05919-0. pmid: 32025755
[15]	Koyner JL, Chawla LS, Bihorac A, et al. Performance of a standardized clinical assay for urinary C-C motif chemokine ligand 14 (CCL14) for persistent severe acute kidney injury[J]. Kidney360, 2022, 3(7): 1158-1168.doi: 10.34067/kid.0008002021.
[16]	Moledina DG, Obeid W, Smith RN, et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis[J]. J Clin Invest, 2023, 133(13):e168950.doi: 10.1172/jci168950.
[17]	Moledina DG, Isguven S, Mcarthur E, et al. Plasma monocyte chemotactic protein-1 is associated with acute kidney injury and death after cardiac operations[J]. Ann Thorac Surg, 2017, 104(2): 613-620.doi: 10.1016/j.athoracsur.2016.11.036. pmid: 28223055
[18]	Peng Y, Wang Q, Jin F, et al. Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients[J]. Ren Fail, 2024, 46(1): 2313171.doi: 10.1080/0886022x.2024.2313171.
[19]	Lee HG, Choi HY, Bae JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease[J]. Kidney Int, 2014, 86(6): 1079-1081.doi: 10.1038/ki.2014.292. pmid: 25427083
[20]	Zhen XW, Song NP, Ma LH, et al. Calprotectin and neutrophil gelatinase-associated lipocalin as biomarkers of acute kidney injury in acute coronary syndrome[J]. Am J Med Sci, 2021, 361(6): 736-743.doi: 10.1016/j.amjms.2020.10.028.
[21]	Yang H, Chen Y, He J, et al. Advances in the diagnosis of early biomarkers for acute kidney injury: A literature review[J]. BMC Nephrol, 2025, 26(1): 115.doi: 10.1186/s12882-025-04040-3. pmid: 40045274
[22]	Schmidt IM, Surapaneni AL, Zhao R, et al. Plasma proteomics of acute tubular injury[J]. Nat Commun, 2024, 15(1): 7368.doi: 10.1038/s41467-024-51304-x. pmid: 39191768
[23]	Pais GM, Avedissian SN, O'donnell JN, et al. Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury[J]. Antimicrob Agents Chemother, 2019, 63(7):e00079-19. doi: 10.1128/aac.00079-19.
[24]	Ibrahim ME, Chang C, Hu Y, et al. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients[J]. Eur J Clin Pharmacol, 2019, 75(1): 51-57.doi: 10.1007/s00228-018-2552-z. pmid: 30220072
[25]	Khorashadi M, Beunders R, Pickkers P, et al. Proenkephalin: A new biomarker for glomerular filtration rate and acute kidney injury[J]. Nephron, 2020, 144(12): 655-661.doi: 10.1159/000509352.
[26]	Donato LJ, Meeusen JW, Lieske JC, et al. Analytical performance of an immunoassay to measure proenkephalin[J]. Clin Biochem, 2018, 58: 72-77.doi: 10.1016/j.clinbiochem.2018.05.010. pmid: 29782819
[27]	Lin LC, Chuan MH, Liu JH, et al. Proenkephalin as a biomarker correlates with acute kidney injury: A systematic review with meta-analysis and trial sequential analysis[J]. Crit Care, 2023, 27(1): 481.doi: 10.1186/s13054-023-04747-5.
[28]	张茜, 赵阳, 崔丽艳. 尿金属蛋白酶组织抑制剂-2与胰岛素样生长因子结合蛋白-7乘积在急性肾损伤的早期诊断、危险分层和预后评估中的研究进展[J]. 中华检验医学杂志, 2021, 44(10): 964-969.doi:10.3760/cma.j.cn114452-20210402-00212.
[29]	Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: An updated review on pathophysiology and management[J]. Intensive Care Med, 2021, 47(8): 835-850.doi: 10.1007/s00134-021-06454-7. pmid: 34213593
[30]	Jia HM, Cheng L, Weng YB, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: A prospective validation study[J]. Ann Intensive Care, 2022, 12(1): 14.doi: 10.1186/s13613-022-00989-8.
[31]	Oosterom-Eijmael MJP, Hermanns H, Lankadeva YR, et al. Cardiac surgery-associated acute kidney injury[J]. BJA Educ, 2026, 26(2): 92-100.doi: 10.1016/j.bjae.2025.11.001.
[32]	Seibert FS, Heringhaus A, Pagonas N, et al. Dickkopf-3 in the prediction of contrast media induced acute kidney injury[J]. J Nephrol, 2021, 34(3): 821-828.doi: 10.1007/s40620-020-00910-1. pmid: 33275197
[33]	Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: A consensus statement[J]. JAMA Netw Open, 2020, 3(10): e2019209.doi: 10.1001/jamanetworkopen.2020.19209.
[34]	Huo R, Dai M, Fan Y, et al. Predictive value of miRNA-29a and miRNA-10a-5p for 28-day mortality in patients with sepsis-induced acute kidney injury[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2017, 37(5): 646-651.doi: 10.3969/j.issn.1673-4254.2017.05.13.
[35]	Xu L, Li J, Li L, et al. Exploring miR-577 and miR-494-3p as emerging biomarkers in sepsis-associated acute kidney injury: Diagnostic and prognostic perspectives[J]. Microbiol Immunol, 2025, 69(5): 297-306.doi: 10.1111/1348-0421.13210.
[36]	Zou YF, Wen D, Zhao Q, et al. Urinary microRNA-30c-5p and microRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury[J]. Exp Biol Med (Maywood), 2017, 242(6): 657-667.doi: 10.1177/1535370216685005.
[37]	Connor KL, Denby L. MicroRNAs as non-invasive biomarkers of renal disease[J]. Nephrol Dial Transplant, 2021, 36(3): 428-429.doi: 10.1093/ndt/gfz183.
[38]	Clementi A, Virzì GM, Ronco C, et al. Urinary and plasma mirnas in the early detection of acute kidney injury and their possible role as therapeutic targets[J]. J Clin Med, 2025, 14(7):2306.doi: 10.3390/jcm14072306.
[39]	Liang L, Li D, Zeng R, et al. Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: The peacp study[J]. Cardiovasc Diabetol, 2023, 22(1): 92.doi: 10.1186/s12933-023-01831-6. pmid: 37081501
[40]	Chen C, Zhang P, Bao G, et al. Discovery of potential biomarkers in acute kidney injury by ultra-high-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (uplc-q/tof-ms)[J]. Int Urol Nephrol, 2021, 53(12): 2635-2643.doi: 10.1007/s11255-021-02829-3. pmid: 33686532
[41]	Lee HS, Kim SM, Jang JH, et al. Serum 5-hydroxyindoleacetic acid and ratio of 5-hydroxyindoleacetic acid to serotonin as metabolomics indicators for acute oxidative stress and inflammation in vancomycin-associated acute kidney injury[J]. Antioxidants (Basel), 2021, 10(6):895.doi: 10.3390/antiox10060895.
[42]	Patschan D, Patschan S, Matyukhin I, et al. Metabolomics in acute kidney injury: The clinical perspective[J]. J Clin Med, 2023, 12(12):4083.doi: 10.3390/jcm12124083.
[43]	Ostermann M, Legrand M, Meersch M, et al. Biomarkers in acute kidney injury[J]. Ann Intensive Care, 2024, 14(1): 145.doi: 10.1186/s13613-024-01360-9. pmid: 39279017
[44]	He T, Lin K, Xiong L, et al. Disorder of phospholipid metabolism in the renal cortex and medulla contributes to acute tubular necrosis in mice after cantharidin exposure using integrative lipidomics and spatial metabolomics[J]. J Pharm Anal, 2025, 15(7): 101210.doi: 10.1016/j.jpha.2025.101210.
[45]	Anandakrishnan N, Yi Z, Sun Z, et al. Liquid biopsy-multiomics link adhesion pathway dysregulation to kidney injury severity[J]. Kidney Int Rep, 2025, 10(10): 3592-3610.doi: 10.1016/j.ekir.2025.07.021. pmid: 41141506

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 45

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Shaoli, Yan Guosheng, Li Lili. Incidence and risk factors of malnutrition-inflammation complex syndrome in patients receiving maintenance hemodialysis at the end stage of renal disease [J]. Clinical Focus, 2026, 41(4): 312-317.
[2]	Wang Yan, Yang Heng. Mediating effect of disease uncertainty on the relationship between health literacy and anxiety in uremic dialysis patients [J]. Clinical Focus, 2026, 41(4): 318-322.
[3]	. [J]. Clinical Focus, 2026, 41(4): 374-379.
[4]	. [J]. Clinical Focus, 2026, 41(1): 84-90.
[5]	Zhang Hui, Zhang Wenbo, Liang Wenqi, Huo Yanhong. Idiopathic renal hypouricemia combined with repeated acute kidney injury: A case report and literature review [J]. Clinical Focus, 2025, 40(2): 168-171.
[6]	Pu Qian, Cheng Gang, Dao Jiecao, Qi Zizhao, Dou Lele, Zhao Junfang, Zhang Wenjun, Guo Caixia, Wang Yingying. Risk factors for constipation in patients with chronic kidney disease in Gansu province: a single-center study [J]. Clinical Focus, 2025, 40(1): 44-53.
[7]	Liu Yi, Zhao Haotian, Wang Xiaona, Liu Yuanlin, Li Li, Wang Zekai. Application value of right heart ultrasound combined with renal vascular doppler score in patients with end-stage renal disease during dialysis [J]. Clinical Focus, 2025, 40(1): 54-59.
[8]	Guo Xiaocui, Yu Xiaojuan, Shen Xia, Ye Shuiying, Zhou Dongchi, Lai Bihong. Effect of a multidisciplinary intervention on the quality of life in maintenance hemodialysis patients [J]. Clinical Focus, 2024, 39(9): 803-807.
[9]	. [J]. Clinical Focus, 2024, 39(9): 847-850.
[10]	. [J]. Clinical Focus, 2024, 39(2): 183-187.
[11]	Wang Lingling, Wu Jinlan, Wu Wei, Shen Shipeng, Chi Yanqing, Liu Maodong. A meta-analysis of the renal protective effects of vitamin D and its analogues in non dialysis patients with chronic kidney disease [J]. Clinical Focus, 2022, 37(12): 1081-1088.
[12]	Wang Pengrui, Chen Huaqian, Yang Tao, Zhao Li, Li Peng. The effect of serum intact parathyroid hormone level on the maturation of autogeneous arteriovenous fistula [J]. Clinical Focus, 2022, 37(12): 1094-1098.
[13]	Li Yingying, Li Ting, Zhang Ming, Fan Minghua, Xing Guangqun. Monitoring significance of CD4⁺ T lymphocyte count on evaluating frailty status of chronic renal failure in patients [J]. Clinical Focus, 2022, 37(3): 243-247.
[14]	Li Wenzhe, Shang Jinchun, Li Chunmei, Tian Fen, Li Jun, Cui Li, Xing Guangqun. Risk factors of cerebral hemorrhage in uremic patients on regular hemodialysis [J]. Clinical Focus, 2022, 37(1): 20-25.
[15]	Li Wenzhe, Shang Jinchun, Li Chunmei, Li Jun, Tian Fen, Cui Li, Chen Yipeng, Zhang Xiaofan, Xing Guangqun. Effect of sodium citrate anticoagulation in continuous renal replacement therapy on uremic patients with cerebral hemorrhage [J]. Clinical Focus, 2021, 36(5): 425-431.